Sign in Sign up for free

Last updated: 6 October 2022 at 4:24pm EST

Philip Pizzo Net Worth




The estimated Net Worth of Philip A. Pizzo is at least $1.24 Million dollars as of 21 June 2022. Philip Pizzo owns over 1,260 units of Global Blood Therapeutics stock worth over $624,081 and over the last 11 years he sold GBT stock worth over $34,335. In addition, he makes $576,995 as Independent Director at Global Blood Therapeutics.

Philip Pizzo GBT stock SEC Form 4 insiders trading

Philip has made over 5 trades of the Global Blood Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,260 units of GBT stock worth $34,335 on 21 June 2022.

The largest trade he's ever made was exercising 30,000 units of Global Blood Therapeutics stock on 11 December 2019 worth over $709,500. On average, Philip trades about 1,294 units every 28 days since 2013. As of 21 June 2022 he still owns at least 9,112 units of Global Blood Therapeutics stock.

You can see the complete history of Philip Pizzo stock trades at the bottom of the page.





Philip Pizzo biography

Dr. Philip A. Pizzo, M.D. is an Independent Director of the Company. Dr. Pizzo currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. He previously served as Dean of the Stanford School of Medicine from 2001 to 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School from 1996 to 2001. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs, has received numerous awards and honors, is a member of the National Academy of Medicine, and serves on several international boards. Dr. Pizzo holds a B.A. from Fordham University and an M.D. from the University of Rochester, School of Medicine. Dr. Pizzo’s qualifications to serve on our Board of Directors include his leadership in academic medicine, and his work in the fields of pediatric medicine, science, education and healthcare.

What is the salary of Philip Pizzo?

As the Independent Director of Global Blood Therapeutics, the total compensation of Philip Pizzo at Global Blood Therapeutics is $576,995. There are 18 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.



How old is Philip Pizzo?

Philip Pizzo is 75, he's been the Independent Director of Global Blood Therapeutics since 2015. There are 1 older and 20 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.

What's Philip Pizzo's mailing address?

Philip's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.



What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.



What does Global Blood Therapeutics's logo look like?

Global Blood Therapeutics Inc. logo

Complete history of Philip Pizzo stock trades at Global Blood Therapeutics and ClearPoint Neuro Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
21 Jun 2022 GBT Global Blood Therapeutics Inc. Philip A. Pizzo
Director
 Sale 1,260 $27.25 $34,335
21 Jun 2022
9,112 ↗
14 Jun 2022 GBT Global Blood Therapeutics Inc. Philip A. Pizzo
Director
 Option 3,600 $22.30 $80,280
14 Jun 2022
10,372 ↗
17 Jun 2021 GBT Global Blood Therapeutics Inc. Philip A. Pizzo
Director
 Option 3,037 $37.09 $112,642
17 Jun 2021
7,837 ↗
17 Jun 2020 GBT Global Blood Therapeutics Inc. Philip A. Pizzo
Director
 Option 4,800 $64.75 $310,800
17 Jun 2020
4,800 ↗
11 Dec 2019 GBT Global Blood Therapeutics Inc. Philip A. Pizzo
Director
 Option 30,000 $23.65 $709,500
11 Dec 2019
30,000 ↗


Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include: